Atlas FDA

TANDEM-R PSA & TANDEM-E PSA IMMUNOENZYMETRIC ASSAY

FDA premarket approval P850048/S012 · decided 1996-05-03

Approval details

PMA number
P850048
Supplement
S012
Supplement type
Normal 180 Day Track
Supplement reason
Change Design/Components/Specifications/Material
Trade name
TANDEM-R PSA & TANDEM-E PSA IMMUNOENZYMETRIC ASSAY
Generic name
PROSTATE-SPECIFIC ANTIGEN (PSA) FOR MANAGEMENT OF PROSTATE CANCERS
Applicant
Beckman Coulter, Inc.
Date received
1995-10-27
Decision date
1996-05-03
Days to decision
189 days
Decision code
APPR
Product code
LTJ
Advisory committee
Immunology
Expedited review
No
Location
Brea, CA
Statement
CHANGE IN HYBRITECH'S IMMUNOENZYMETRIC PSA ASSAY FROM A BEAD FORMAT TO A MICROPLATE (MP) FORMAT (TANDEM-MP PSA ASSAY)

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Access BNP II (K252169)Beckman Coulter, Inc.2026-03-24
Access anti-HBc IgM (K254059)Beckman Coulter, Inc.2026-03-13
Access anti-HBc Total (K253687)Beckman Coulter, Inc.2026-02-19
Access anti-HAV IgM (K251995)Beckman Coulter, Inc.2026-01-27
Access Rubella IgG (K250588)Beckman Coulter, Inc.2025-11-17
iQ200 Series (K252580)Beckman Coulter, Inc.2025-09-10
Access anti-HAV (K243846)Beckman Coulter, Inc.2025-09-09
MicroScan Dried Gram-Negative MIC/Combo Panels with Cefepime (CPE) (0.12-64 µg/mL) (MicroScan) (K243804)Beckman Coulter, Inc.2025-08-20